

**Supplemental Table S4.** Sensitivity Analysis of End-Stage Kidney Disease by Excluding Perkovic, 2019 (CREDENCE) Study

	Placebo	DPP-4 inhibitors	SGLT2 inhibitors
End-stage kidney disease			
Placebo	1		
DPP-4 inhibitors	1.05 (0.72–2.43)	1	
SGLT2 inhibitors	0.56 (0.28–1.00)	0.53 (0.16–1.03)	1

Values are expressed as median odds ratios (95% credible intervals).  
CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose cotransporter 2.